Diabetes prevention in Asia and worldwide

 

Metabolic benefits of incremental weight loss

 

Diagnosis of diabetes by A1C in Asia

 

Recent trial to prevent CV disease: Is this the Answer or has it created more questions?
        

 

Glucosidan INH - First line therapy Vs. metformin

 

GLP1/DPP4 INH Vs. Sulfonylurea / Insulin / TZDs
Pro:
Con:

Initiation of insulin
Not too early:
Not too late:

 

Combinations of Oral Hypoglycemic (OAD) with long-acting analogs

 

Place of TZD in Asian diabetic patients

           

Insulin, metformin TZD, glucosidase INH

 

Combination therapy and lifestyle modifications (based on preliminary results from TODAY study)

     

Hypertension as a vascular disease

 

The endothelium as a target for therapy

 

Vascular and endothelial function

 

Vasculature in obesity, diabetes and hypertension

    

Should we aim to normalize A1c?
Pro:
Con:

 

The glucotriad: Is glucose variability a cardiovascular (CV) risk factor in its own right?
Pro:
Con:

                

Key role of glucose control
Pro:
Con:

Key role of blood pressure (BP) Control
Pro:
Con:

Key role of lipid control
Pro:
Con:

 

 

Cardiometabolic risk assessment and metabolic syndrome controversies

  

Programmed insulin dose calculation
Pro:
Con:

  
Benefit of self - monitoring glucose control

Pro:
Con:
 

Continuous glucose monitoring (CGM): For whom will it be beneficial? 

  

Hyperglycemia and CVD
 

Dyslipemia and CVD
 

Hypertension and CVD
 

Inflammation and CVD
 

Cultural obesity